Publication:
Biosimilars

dc.contributor.authorBaşkan, Emel Bülbül
dc.contributor.buuauthorBÜLBÜL BAŞKAN, EMEL
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı
dc.date.accessioned2024-09-10T12:02:03Z
dc.date.available2024-09-10T12:02:03Z
dc.date.issued2022-01-01
dc.description.abstractFor a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.
dc.identifier.doi10.4274/turkderm.galenos.2022.06978
dc.identifier.endpage76
dc.identifier.issn2717-6398
dc.identifier.startpage75
dc.identifier.urihttps://doi.org/10.4274/turkderm.galenos.2022.06978
dc.identifier.urihttps://hdl.handle.net/11452/44503
dc.identifier.urihttps://jag.journalagent.com/turkderm/pdfs/TURKDERM_56_50_75_76.pdf
dc.identifier.volume56
dc.identifier.wos000840123800020
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherGalenos Yayıncılık
dc.relation.journalTürk Dermatoloji ve Zührevi Hastalıklar
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.subjectPsoriasis
dc.subjectBiosimilars
dc.subjectBiologics
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectDermatology
dc.titleBiosimilars
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublication5bd3accb-bb59-411b-8d6c-46d06d35b5a4
relation.isAuthorOfPublication.latestForDiscovery5bd3accb-bb59-411b-8d6c-46d06d35b5a4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Başkan_2022.pdf
Size:
102.51 KB
Format:
Adobe Portable Document Format

Collections